Peptides DB
Research-centric peptide and protocol reference hub

Tesofensine record · updated 17h ago

Metabolic & appetiteNeuro & moodGrade A · human clinicalResearch use only
All 16 studiesJump to the evidenceCompare
What is Tesofensine used for?

Tesofensine is a novel compound initially developed as an antidepressant, which has gained attention for its potential effects on weight loss and metabolic regulation. Research indicates that it may influence neurotransmitter levels, thereby affecting appetite and energy expenditure.

How it works: Triple reuptake inhibitor (serotonin, norepinephrine, dopamine)

Primarily researched for · Metabolic & appetite

Development stage

where Tesofensine sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 14 registered trials. It describes the research record, not a recommendation.

Identity
NameTesofensine
Chain length—
Molecular weight328.3 Da
FormulaC17H23Cl2NO
Structure typeSmall molecule
ClassMetabolic
Research levelModerate Research
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 11370864. No verified residue count for this compound.

Pharmacology
MechanismTriple reuptake inhibitor (serotonin, norepinephrine, dopamine)
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 28, 2026. How this works →
Research stats
Total studies16
Human / animal / cellular8 / 2 / 3
Highest trial phasePhase 1
Years covered2010–2026
Latest study5d ago
Publication history
20102026
Research funding
—no NIH grants found
Safety signals
FAERS reports11
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

16 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Structural brain alterations in chronic primary pain: a multimodal MRI study.
FindingIncreased gyrification in left prefrontal regions in CPP patients.
Human2026Full text read0.80
HSP101-encoding NEO-TETRAPLOID RICE FERTILITY GENE 1 regulates tapetum development through interaction with SAPK2 in polyploid rice.
FindingSignificantly reduced seed-setting rate in ntrf1 mutants due to pollen developmental defects.
In vitro2026Full text read0.80
Design and evaluation of a novel peptide-EV complex for targeted Alzheimer's disease therapy.
FindingNear-complete suppression of Aβ fibrillation at 100 µM.
In vitro2026Full text read0.70
Plasma membrane transporters Alp1 and Nrt1 mediate the uptake of benzamidine conjugates in fungi.
TakeawayAlp1 and Nrt1 transporters are crucial for the uptake and antifungal activity of benzamidine conjugates in fungi, offering insights into overcoming resistance.
In vitro2026Full text read0.80
Chronic High-Fat Diet Does Not Alter Overall Cancer Incidence in Trp53R270H/+ Mice.
FindingNo significant effect on overall survival or tumor burden in Trp53R270H/+ mice after more than 1 year of HFD.
Animal2026Full text read0.90
Ultrasensitive Chemical Detection Using Integrating Cavity-Enhanced Raman Spectroscopy.
FindingPeak average reflectivity of 99.943 ± 0.0004% at 610 nm.
review2026Full text read0.70
Risk of Falls and Need of Walking Aid in Parkinson's Disease: Incidence and Impact of Comorbidities.
Finding66.5% experienced falls 10 years after diagnosis.
Human2026Full text read0.80
The Long-Term Impact of Adolescent Community Weapon-Related Violence Exposure on Depression: Insomnia as a Mediating Pathway.
FindingInsomnia accounted for 7% of the total effect of weapon-related violence on depressive symptoms.
Human2026Full text read0.80
The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.
FindingNot reported in abstract.
Animal2026Full text read0.70
Epidemiology and severity of pediatric influenza hospitalizations before and during the COVID-19 pandemic: a surveillance study of the Canadian immunization monitoring program (IMPACT), 2012-2023.
FindingOdds of severe disease lower in 2021-2022 (aOR 0.63, 95% CI 0.44-0.89) and 2022-2023 (aOR 0.85, 95% CI 0.74-0.98) compared to pre-pandemic.
Human2026Full text read0.90
Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.
FindingNot reported in abstract.
review2026Full text read0.80
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.
FindingMean striatal SERT occupancy was 72% at 4-6 h post-dose, n=6.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Tesofensine will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Tesofensine is discussed should be drawn from it.